{"entity":{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","aka":["Lancet Oncol","src-lancet-oncology"],"tldr":"The Lancet Oncology is the leading specialist cancer journal for clinical trials. It publishes phase 2 and 3 trials, long-term follow-up, quality-of-life analyses and global-oncology policy Commissions.","summary":"The Lancet Oncology appears monthly plus online-first and publishes a large share of randomised oncology trials that do not go to NEJM, with particular strength in radiotherapy, surgery, supportive care and health-system studies (IBIS-I tamoxifen prevention, MASAI AI mammography, GAP70 geriatric assessment in this corpus). Its Commissions and Series drive policy debates on drug pricing, radiotherapy access and cancer in low-income countries. Elsevier hybrid model; abstracts free.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/The_Lancet_Oncology","links":[{"label":"Lancet Oncology Commissions","url":"https://www.thelancet.com/journals/lanonc/commissions"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Phase 2 and 3 trials, meta-analyses, global oncology policy and the ESMO-aligned commentaries. Access: Paywalled; abstracts free."],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/lanonc/home","issn":"1470-2045","scope":"clinical oncology","access":"hybrid","founded":2000,"impactFactor":{"value":41.6,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Lancet Oncology","The Lancet Oncology","Lancet Oncol"]},"route":"/journals/lancet-oncology/","neighbours":{"person":[{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/"}]}}